Why the study?
Do cerebral protection devices reduce procedural cerebral thromboembolic events in patients undergoing transcatheter aortic valve implantation for symptomatic severe aortic stenosis?
Do cerebral protection devices reduce procedural cerebral thromboembolic events in patients undergoing transcatheter aortic valve implantation for symptomatic severe aortic stenosis?
This review evaluates the current evidence for four available cerebral protection devices designed to reduce periprocedural stroke risk during transcatheter aortic valve implantation.
Evidence on cerebral protection devices in TAVI remains limited; leaves open their routine use pending randomized trials.
Transcatheter aortic valve implantation is a widely performed procedure for treatment of symptomatic severe aortic stenosis. According to the current literature, major stroke has been reported as occurring in 3-6% of patients during the first 30 days following valve implantation. Several pathological mechanisms may be involved in the development of periprocedural ischaemic stroke with the majority being due to thromboembolism and atheroembolism. One approach to reduce the incidence of procedural cerebral thromboembolic events is the use of cerebral protection devices, either deflecting (Embrella, TriGuard) or capturing (Claret, Embol-X) embolic material. We decided to review the current evidence on this important issue focusing on the four cerebral protection devices currently available.
No takes yet. Share an insight, caveat, or question.
Praz et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: